Stocks · News reference
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:08 AM
- Checked
- Jul 28, 2026, 11:08 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
Read original at benzingaOKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share
Read original at benzinga